Memory Inhibition and Delayed Onset Post-traumatic Stress Disorder in Older Subjects (I-TSPT-R)

July 29, 2021 updated by: Centre Hospitalier de Niort

In the elderly, we can see a post-traumatic syndrome associated with an event that occurred before old age that had not previously manifested or not fully manifested.

This little-known pathology and notable psychiatric co-morbidities (depression, anxiety) can take in elderly subjects different masks that interfere with diagnosis and treatment.

The data in the literature suggest that this Post-Traumatic Stress Disorder with Delayed Expression (TSPT-R) may be related to a deficiency of the executive functions of inhibition, and more particularly a deficit of mental memory inhibition and therefore the removal of unwanted memories.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Niort, France, 79021
        • Centre Hospitalier de Niort

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 85 years (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

-

Regarding the constitution of the group patient (TSPT-R):

  • Subjects 65 years of age or older
  • Clinical diagnosis of delayed-onset PTSD according to DSM-5 criteria after 65 years
  • The traumatic event must have taken place at the latest before 65 years
  • Affiliated person or beneficiary of a social security scheme.
  • Written consent before any examination required by research)

Regarding the constitution of the control group:

  • Subjects 65 years of age or older
  • No diagnosis of PTSD (delayed or not) or history of PTSD (delayed or not)
  • Affiliated person or beneficiary of a social security scheme.
  • Written consent before any examination required by the research).

Exclusion Criteria:

  • For both groups:
  • Acute or chronic cognitive impairment known

  • GRECO MMSE pathological score less than or equal to the pathological threshold weighted according to level of education and age, namely:

    • 22 if no diploma
    • 23 if certificate of study
    • 25 if patent
    • 26 if bin or more
    • Remove one point at each threshold if age> 80 years
  • Sensory or motor disorder preventing the passing of different tests
  • Psychotic disorder
  • Mood disorder in decompensation (for depression, HAD-D score equal to or greater than 11)
  • Disorder of the use of a moderate or severe substance (except tobacco).
  • Patients under guardianship or curatorship.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Patient (TSPT-R)
Post Traumatic Stress Disorder
Other: Post Traumatic Stress Disorder
The test "Think / No-Think"
Experimental: control
No Post Traumatic Stress Disorder
Other: Post Traumatic Stress Disorder
The test "Think / No-Think"

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inhibition score measured by the Think / No-Think Test
Time Frame: 1 month
the average of the inhibition score measured by the "Think / No-Think" test as defined by Anderson and Green (2001) and then reviewed by Anderson et al. in 2011
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier de Niort

Investigators

  • Study Director: Dominique LEGER, Doctor, Centre Hospitalier de Niort

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2019

Primary Completion (Actual)

April 15, 2019

Study Completion (Actual)

March 26, 2021

Study Registration Dates

First Submitted

March 29, 2019

First Submitted That Met QC Criteria

March 29, 2019

First Posted (Actual)

April 1, 2019

Study Record Updates

Last Update Posted (Actual)

July 30, 2021

Last Update Submitted That Met QC Criteria

July 29, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CH-NIORT-2018-02

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe